Country: United States
Language: English
Source: NLM (National Library of Medicine)
ISOSORBIDE MONONITRATE (UNII: LX1OH63030) (ISOSORBIDE - UNII:WXR179L51S)
West-ward Pharmaceutical Corp
ISOSORBIDE MONONITRATE
ISOSORBIDE MONONITRATE 20 mg
ORAL
PRESCRIPTION DRUG
Isosorbide mononitrate is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Allergic reactions to organic nitrates are extremely rare, but they do occur. Isosorbide mononitrate is contraindicated in patients who are allergic to it.
Isosorbide Mononitrate Tablets 20 mg: white coated, round, scored tablet; embossed "WW33". Bottles of 30 tablets. Bottles of 90 tablets. Bottles of 100 tablets. Bottles of 1000 tablets. Store at 20-25°C (68-77°F). [See USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured by: West-ward Pharmaceutical Corp. Eatontown, NJ 07724 USA Revised April 2006
Abbreviated New Drug Application
ISOSORBIDE MONONITRATE- ISOSORBIDE MONONITRATE TABLET, COATED WEST-WARD PHARMACEUTICAL CORP ---------- ISOSORBIDE MONONITRATE TABLETS RX ONLY DESCRIPTION Isosorbide mononitrate, an organic nitrate, is a vasodilator with effects on both arteries and veins. The molecular formula is C H NO and the molecular weight is 191.14. The chemical name for isosorbide mononitrate is 1,4:3,6-Dianhydro-D-glucitol 5-nitrate and the compound has the following structural formula: Isosorbide mononitrate tablets, for oral administration, contain 20 mg of isosorbide mononitrate. In addition, each white tablet contains the following inactive ingredients: Colloidal Silicon Dioxide, Dibasic Ammonium Phosphate, Lactose Monohydrate, Microcrystalline Cellulose, Povidone, and Sodium Starch Glycolate. Film coating contains: Hydroxypropyl Methylcellulose, Polyethylene Glycol, and Titanium Dioxide. CLINICAL PHARMACOLOGY Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate (ISDN), and most of the clinical activity of the dinitrate is attributable to the mononitrate. The principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction and coronary dilatation remains undefined. PHARMACODYNAMICS: Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration. This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exer Read the complete document